| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 28.78 | 0.08 (+0.28%) | 21.40 - 31.15 | 44.1 million (Above Avg) |
Market data as of 4:01PM 05/21/13. Quotes are delayed by at least 15 min.
Pfizer Discontinues Phase 3 Study of Inotuzumab Ozogamicin in Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma (NHL) Due to Futility
05/20/2013 5:01 PM ET
Pfizer Announces 11 Abstracts for Tofacitinib to Be Presented at the European League Against Rheumatism (EULAR) 2013 Annual Meeting
05/13/2013 8:00 AM ET
Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference
05/08/2013 4:00 PM ET